Navigation Links
5,000 Patients Treated With OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Now Enrolled in Real-Life Use Global Registry
Date:11/8/2007

Enrollment Reaches Milestone as Interim Data Show Pro-Healing Stent

Performs Comparably to Drug-Eluting Stents

HONG KONG, Nov. 8 /PRNewswire/ -- OrbusNeich today reported that 5,000 patients treated with the company's Genous stent at more than 120 sites in 29 countries are now enrolled in the global e-HEALING registry.

OrbusNeich's e-HEALING clinical study is a monitored multi-center, worldwide (outside the United States) prospective registry of patients treated with the Genous Bio-engineered R stent. The study protocol recommends that patients receive one month of clopidogrel treatment after the procedure. Clinical follow-up takes place at 30 days, six months and 12 months. The primary endpoint of the registry is target vessel failure at 12 months.

"We reached this significant enrollment milestone earlier than we expected," said Sigmund Silber, M.D., F.A.C.C., F.E.S.C., professor of medicine, a co-principal investigator of the study. "This reflects an increase in demand and use for Genous by physicians concerned with drug- eluting stents."

Robbert de Winter, M.D., Ph.D., F.E.S.C., a co-principal investigator of the study and director of the catheterization laboratory at the Academic Medical Center in Amsterdam, added: "We look forward to our continued reporting of the patient follow-up data. Our next presentation is expected to be at the American College of Cardiology's annual scientific session early next year."

Unlike drug-eluting stents, Genous is coated with an antibody that captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.

"Completing enrollment in this large registry is an important milestone in our clinical development," said Samuel Rasmussen, OrbusNeich's president and CEO.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. In addition to Genous OrbusNeich's products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products in more than 60 countries. For more information, visit http://www.OrbusNeich.com.


'/>"/>
SOURCE OrbusNeich
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Governor Rendell Offers adultBasic Coverage to 35,000 Uninsured Pennsylvanians
2. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
3. Plexus Systems Ranks in Top Third of the 2007 Inc. 5,000 with Three-Year Sales Growth of 226%
4. Whole Foods Market(R) Donates $25,000, for Midwest Farmers - Hoping to Match an Additional $10,000, via Customer Donations
5. Donation of $15,000 and Hard Work Allows a Family in Need to Move into New Home
6. TriWest Contributes $25,000 to Iowa National Guard Fund and Sponsors Education for Teachers of Military Children
7. 18th Annual CATCH Night of Champions Raises $225,000 To Help Support Local Youth
8. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
9. Comparison of obstetric outcomes between on-call and patients own obstetricians
10. Vision restoration therapy shown to improve brain activity in brain injured patients
11. Diabetes appears to increase risk of death for patients with acute coronary syndromes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 2017 , ... First Healthcare Compliance (FHC), an industry leader ... range of technology and learning solutions at the 68th Annual American Healthcare Association ... held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, Nevada. ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... products to meet the demand of today’s consumer and regulatory authorities worldwide. From ... probiotic experts and tested to meet the highest standard. , These products ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized health ... expanded their existing home health joint venture through an agreement, effective October 1, ... joint venture home health company with Asante, delivering clinically integrated care, for the ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand ... Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be ... Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/10/2017)...   West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today shared the results of a study highlighting ... intradermal administration of polio vaccines. The study results were ... 2017 by Dr. Ondrej Mach , Clinical Trials ... (WHO), and recently published in the journal Vaccine. ...
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare ... CPR training aide "cprCUBE" on Kickstarter. The device will ... during cardiac arrests with better efficiency compared to the ... offers real-time feedback on efficacy of the compression for ... campaign has a goal to raise $5,000. ...
Breaking Medicine Technology: